In this Issue
- Lykos’ Path to FDA Approval Might Include a Third-Party Review of Phase 3 Data, VA Funding of Phase 3 ‘Definitely a Possibility’
- Precision Psychiatry Platform Under Pressure as Alto’s ALTO-100 Fails in MDD Trial
- Antidepressant Withdrawal Doesn’t Diminish Psilocybin Efficacy, Compass Study Suggests
- Massachusetts Miscellany: MAPS Boosts Funding for Yes on Question 4
- Czech Republic Establishes Unique Category for Low-Risk Psychoactive Substances, Skirting International Drug Controls
- Other Stories, including: Eli Lilly’s Alzheimer’s Drug Blocked from UK Coverage by NICE, Citing High Costs; SXSW’s 2025 Psychedelics Line-Up; Imperial Wins UK Government Funding for Psilocybin Study; Seaport Therapeutics Scoops $225M Series B; FDA Issues Complete Response Letter to PharmaTher; and more.
***
Lykos’ Path to FDA Approval Might Include a Third-Party Review of Phase 3 Data, VA Help
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue